ABSTRACT
INTRODUCTION: This meta-analysis aimed to identify the effect of colchicine on myocardial infarction (MI) in patients with gout. METHODS: In February 2021, a systematic computer-based search was conducted in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Data on patients with gout that compared colchicine versus others (no use of colchicine) were retrieved. The endpoints were the incidence rate for MI. After testing for heterogeneity between studies, data were aggregated for fixed-effects models when necessary. RESULTS: Three clinical studies with 3012 patients (colchicine groupâ¯= 1523, control groupâ¯= 1489) were finally included in the meta-analysis. Colchicine was associated with a decreased risk for myocardial infarction (pooled odds ratio 0.35, 95% confidence interval 0.23-0.55, pâ¯< 0.00001). CONCLUSIONS: Colchicine was effective in reducing the incidence of MI in patients with gout.
